GCS
GTBP icon

Gordian Capital (Singapore)’s GT Biopharma GTBP Stock Holding History

Gordian Capital (Singapore)’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,167
Closed -$103K – 125
2022
Q2 		$103K Hold
1,167
– – 0.14% 57
2022
Q1 		$3K Hold
1,167
– – ﹤0.01% 106
2021
Q4 		$107K Buy
+1,167
New +$175K 0.09% 72

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Gordian Capital (Singapore)'s GTBP Position: Q3 2022 in Review

Gordian Capital (Singapore) sold out of GT Biopharma (GTBP) in Q3 2022, closing a stake of 1,167 shares — an estimated $103K sold.

Gordian Capital (Singapore) first reported a position in GTBP in Q4 2021 and held it in 3 quarters. The position peaked at $107K in Q4 2021. 34 funds tracked by Wall St. Rank hold GTBP as of Q3 2022.

  • Gordian Capital (Singapore) reported no remaining GT Biopharma position as of Q3 2022 after selling out during the quarter.
  • Gordian Capital (Singapore) sold 1,167 GT Biopharma shares in Q3 2022, an estimated $103K.
  • Gordian Capital (Singapore) first reported a position in GT Biopharma in Q4 2021 and held it in 3 quarters.
  • Gordian Capital (Singapore)'s GT Biopharma position peaked at $107K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2022.

Based on Gordian Capital (Singapore)'s 13F filing for Q3 2022, filed 14 Nov 2022.